Drug Profile


Alternative Names: Asacol; Asacolon; Fivasa; Lixacol; Octasa; TP 05; Z-206

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tillotts Pharma
  • Developer Kyowa Hakko Kirin; Lek Pharmaceuticals d.d.; Tillotts Pharma; Zeria
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Proctitis; Ulcerative colitis
  • Phase II Irritable bowel syndrome

Most Recent Events

  • 16 Jun 2017 Registered for Ulcerative colitis in Japan (PO, controlled release, od) (Zeria pipeline, June 2017)
  • 01 Feb 2017 Tillotts Pharma completes a phase II trial in Irritable bowel syndrome in Sweden (PO) (NCT01699438)
  • 04 Aug 2016 Preregistration for Ulcerative colitis in Japan (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top